Condition: Refractory or Relapsed B-cell Non-Hodgkin Lymphoma · Sponsor: Aibin Liang，MD，Ph.D.
To find the highest tolerable dose of dualCAR-NK19/70 (a type of cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.
This description comes directly from the study's public registry record.
aibin Liang · 18601670600 · lab7182@tongji.edu.cn
Ping Li · 13564181131 · lilyforever76@126.com
Always discuss trial participation with your own doctor first.
| Shanghai Tongji Hospital, Tongji University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05842707